Tatva Chintan Pharma Chem Limited (TATVA) — Corporate Action | 16 May 2026

Tatva Chintan Pharma Chem Limited announced on 16 May 2026 its audited financial results for FY2025-26, recommending a final dividend of Rs 2 per share (20% of Rs 10 face value) subject to shareholder approval. The board also appointed Zarna Thakar & Associates as cost auditor and RSM Astute Consultech as internal auditor for FY2026-27. The financials show a net profit of Rs 1,005.92 lakhs, with total income at Rs 5,094.07 lakhs and total expenses at Rs 4,016.13 lakhs. The auditor issued an unmodified opinion, confirming compliance with SEBI regulations. The dividend translates to a yield of approximately 2% based on current market price.